FDA approves MED-EL SYNCHRONY cochlear implant for infants as young as seven months

USA— The US Food and Drug Administration has approved MED-EL’s SYNCHRONY cochlear implant system to treat infants aged seven months and older who have bilateral sensorineural hearing loss.

The Austria-based hearables company announced that this expanded indication makes their device the only FDA-approved cochlear implant option available for infants in this age group.

This regulatory milestone opens new possibilities for families whose young children face significant hearing challenges.

The earlier approval means that infants can now access sound and begin developing speech capabilities at a much younger age than previously possible.

Beyond infants, the FDA’s latest decision also extends audiologic and speech indications for children aged 12 months and older, broadening the potential patient population that can benefit from this technology.

Bilateral sensorineural hearing loss affects both ears and causes permanent hearing impairment.

The condition develops when damage occurs to the hair cells within the inner ear or to the auditory nerve itself.

Multiple factors can trigger this type of hearing loss, ranging from viral infections and autoimmune disorders to physical trauma affecting the head or ears.

The World Health Organization projects that up to 900 million people worldwide could experience disabling sensorineural hearing loss by 2050, highlighting the growing need for effective treatment solutions.

The SYNCHRONY implant system uses a two-part design to restore hearing function.

An audio processor sits on the outer ear, capturing sound waves from the environment and converting them into electrical signals.

 These signals then travel to the implant positioned beneath the skin.

The implant generates electrical pulses that stimulate the cochlea directly, allowing sound signals to reach the brain and enabling the user to perceive sound.

John Sparacio, president and CEO of MED-EL USA, emphasized the significance of this approval for families navigating childhood hearing loss.

He noted that providing children with access to sound as early as possible creates opportunities that can fundamentally shape their developmental trajectory and future outcomes.

MED-EL continues to expand the applications of its cochlear implant technology across different patient groups.

 In 2024, the company secured an indication expansion for adults with bilateral moderate-to-profound sensorineural hearing loss.

The expanded approval covers adults whose aided word recognition scores reach 50% or less in the ear receiving the implant and 60% or less in the other ear.

The hearables market has seen notable activity from major technology companies as well.

Apple entered this space last year after receiving FDA authorization for its over-the-counter hearing aid software, which works with compatible versions of the AirPods Pro headphones.

This move brought hearing assistance technology to a consumer electronics platform that millions already use daily.

Market analysts at GlobalData have identified smartwatches and hearables as the leading segments within the wearables industry, noting that these categories have demonstrated the strongest growth patterns in recent years.

The firm’s 2023 report forecasts substantial expansion for the global wearable technology market, projecting growth from USD99.5 billion in 2022 to USD290.6 billion by 2030.